- Conditions
- Hepatocellular Carcinoma
- Interventions
- Nivolumab, Sorafenib, Ipilimumab, Cabozantinib
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Pensacola, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 695
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Hepatitis C
- Interventions
- Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
- Drug
- Lead sponsor
- InterMune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Hepatitis B, Chronic
- Interventions
- Entecavir, Tenofovir, Adefovir, Lamivudine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 629 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Glecaprevir/Pibrentasvir
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more
- Conditions
- Hepatitis C, Chronic, Lung Transplant
- Interventions
- Epclusa
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hepatitis C
- Interventions
- FK788
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 9
- States / cities
- Pasadena, California • Lakewood, Colorado • Gainsville, Florida + 6 more
- Conditions
- Hepatitis D
- Interventions
- Peginterferon Alpha-2a
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C, Chronic, Pregnancy; Infection
- Interventions
- Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
- Drug
- Lead sponsor
- Catherine Anne Chappell
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Interventions
- Ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis B
- Interventions
- Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Indianapolis, Indiana • New Orleans, Louisiana + 6 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Liver Biopsy, Peginterferon & Ribavirin for Hepatitis C, Pre-treatment Ribavirin
- Procedure · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Hepatitis B
- Interventions
- ABI-H2158, Placebo, Entecavir (ETV)
- Drug
- Lead sponsor
- Assembly Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Pasadena, California • Redwood City, California + 10 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fresno, California + 86 more
- Conditions
- Genotype 1 Chronic Hepatitis C
- Interventions
- GI-5005, Pegylated Interferon and Ribavirin
- Drug
- Lead sponsor
- GlobeImmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection Genotype 1
- Interventions
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 615 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more
- Conditions
- Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Alcoholic, Hepatitis, Chronic, Hepatitis, Viral, Human
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,871 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2020
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- ABT-267, ABT-450, ABT-333, Ritonavir, Ribavirin
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Orlando, Florida • Annapolis, Maryland + 1 more
- Conditions
- HBeAg-positive Chronic Hepatitis B
- Interventions
- TAF, TDF, TAF Placebo, TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Viramidine, Ribavirin, pegylated interferon alfa-2a
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 53
- States / cities
- Tucson, Arizona • Fresno, California • Los Angeles, California + 42 more
- Conditions
- Chronic Hepatitis B
- Interventions
- Peginterferon alfa-2a
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C
- Interventions
- On Plan
- Other
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Hepatitis B
- Interventions
- JNJ-56136379, Placebo, NA (ETV or TDF)
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 7
- States / cities
- Bakersfield, California • Orlando, Florida • Chicago, Illinois + 4 more
- Conditions
- Liver Cirrhosis, Chronic Hepatitis C
- Interventions
- Rifaximin, Placebo
- Drug
- Lead sponsor
- David E. Kaplan, MD MSc
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatitis C, Chronic
- Interventions
- ISIS 14803
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Carlsbad, California